Spontaneous reporting of adverse reactions associated with the COVID-19 vaccine in health care professionals: A descriptive observational study conducted in a Portuguese hospital

ABSTRACT Background: The coronavirus disease 2019 (COVID-19) was classified as a pandemic in March 2020 by the World Health Organization. The Pfizer-BioNTech COVID-19 vaccine was the first to be authorized in the European Union, based on data from phase 1, 2, and 3 clinical trials of limited duration. Concerns have been raised regarding the vaccine's safety profile. Some of the adverse drug reactions (ADRs) associated with vaccines may not have been identified during clinical trials. This study aimed to identify ADRs associated with the Pfizer-BioNTech vaccine in health care professionals at a Portuguese tertiary university hospital. Methods: The data used in this analysis consist of ADRs reported through a spontaneous notification system from vaccines administered between December 27, 2020, and January 31, 2021. ADRs were categorized according to the MedDRA terminology. Results: A total of 8,605 Pfizer-BioNTech vaccines were administered to 4568 health care professionals. ADRs were reported among 520 of the vaccines, with an incidence of 13.56% in women and 5.31% in men. The mean age of the population reporting ADRs was 41.52 years, with a standard deviation of 9.83 years. The most frequent ADRs were myalgia (n = 274), headache (n = 199), pyrexia (n = 164), injection site pain (n = 160), fatigue (n = 84), nausea (n = 81), chills (n = 65), lymphadenopathy (n = 64), and arthralgia (n = 53). Hypersensitivity reactions occurred in 15 health care professionals, with no anaphylactic reactions observed. A total of four Important Medical Events were observed, which consisted of two cases of syncope, one case of sudden hearing loss, and one case of transverse myelitis. Conclusion: The vaccine was well-tolerated among the study participants. Reactogenicity was greater after the second dose. The incidence of ADRs was higher in women and individuals aged between 40 to 49 years. Systemic adverse reactions were most frequently reported. Systematic monitoring of ADRs of COVID-19 vaccines in real-life context is essential for a more robust establishment of its safety profile.

[1]  Ojbindra Kc,et al.  A Rare Case of Longitudinally Extensive Transverse Myelitis Following Pfizer-BioNTech COVID-19 Vaccination with a Favourable Outcome , 2022, European journal of case reports in internal medicine.

[2]  T. Nieminen,et al.  Sudden hearing loss following vaccination against COVID-19 , 2022, medRxiv.

[3]  S. Anvari,et al.  Hypersensitivity Reactions to COVID-19 Vaccines-Identify High-Risk Children and Vaccinate the Rest. , 2022, JAMA pediatrics.

[4]  T. Sawa,et al.  Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers , 2022, Journal of Infection and Chemotherapy.

[5]  J. Guarnaccia,et al.  Transverse myelitis as a first event of multiple sclerosis precipitated by Pfizer-BioNTech COVID-19 vaccination , 2022, Neuroimmunology Reports.

[6]  N. Randhawa,et al.  Incomplete Subacute Transverse Myelitis Following Vaccination With Pfizer-BioNTech COVID-19 mRNA Vaccine: A Case Report , 2021, Cureus.

[7]  J. Olgin,et al.  Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination , 2021, JAMA network open.

[8]  J. Al-Tawfiq,et al.  Early solicited adverse events following the BNT162b2 mRNA vaccination, a population survey from Saudi Arabia , 2021, Preventive medicine reports.

[9]  Ahmed N. Alghamdi,et al.  BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees , 2021, Frontiers in Medicine.

[10]  A. Shrestha,et al.  Acute transverse myelitis following SARS-CoV-2 vaccination: a case report and review of literature , 2021, Journal of Neurology.

[11]  Yan Yan,et al.  Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan , 2021, Journal of Infection and Chemotherapy.

[12]  M. Klugar,et al.  Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia , 2021, Pharmaceuticals.

[13]  A. Rodríguez-Morales,et al.  Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems , 2021, Drugs & Therapy Perspectives.

[14]  M. Mekhemar,et al.  Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers , 2021, Biology.

[15]  N. Realdon,et al.  Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021 , 2021, European journal of hospital pharmacy : science and practice.

[16]  S. Ladhani,et al.  Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[17]  Joon Seo Lim,et al.  Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea , 2021, Journal of Korean medical science.

[18]  J. Gee,et al.  Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines. , 2021, JAMA.

[19]  B. Alghamdi,et al.  Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study , 2021, International journal of general medicine.

[20]  Sameh Attia,et al.  Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic , 2021, Journal of clinical medicine.

[21]  M. Sotir,et al.  First Month of COVID-19 Vaccine Safety Monitoring — United States, December 14, 2020–January 13, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[22]  WHO ISSUES ITS FIRST EMERGENCY USE VALIDATION FOR A COVID-19 VACCINE AND EMPHASIZES NEED FOR EQUITABLE GLOBAL ACCESS , 2021, Saudi Medical Journal.

[23]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[24]  A. Rodríguez-Morales,et al.  SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic , 2020, Annals of clinical microbiology and antimicrobials.

[25]  V. Paudyal,et al.  Interventions to improve spontaneous adverse drug reaction reporting by healthcare professionals and patients: systematic review and meta-analysis , 2020, Expert opinion on drug safety.

[26]  R. Williams,et al.  The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation , 2020, AAPS PharmSciTech.

[27]  A. Rodríguez-Morales,et al.  A vaccine is not too far for COVID-19. , 2020, Journal of infection in developing countries.

[28]  Subish Palaian,et al.  Bibliometric analysis of adverse drug reactions and pharmacovigilance research activities in Nepal , 2020, Therapeutic advances in drug safety.

[29]  Qianyun Liu,et al.  Emerging coronaviruses: Genome structure, replication, and pathogenesis , 2020, Journal of medical virology.

[30]  X. Mariette,et al.  Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. , 2013, Rheumatology.